SHAREHOLDERS' EQUITY (Tables)
|
6 Months Ended |
Jun. 30, 2026 |
|---|
| Stockholders' Equity Note [Abstract] |
|
| Schedule of ordinary shares reserved for future issuance |
| |
|
June 30,
|
|
|
December 31,
|
|
| |
|
2026
|
|
|
2025
|
|
| |
|
(Unaudited)
|
|
|
|
|
|
Ordinary shares
|
|
|
42,274,119
|
|
|
|
51,160,822
|
|
|
Outstanding share options and RSUs
|
|
|
3,755,167
|
|
|
|
2,653,964
|
|
|
Shares available for future grants under the 2021 plan
|
|
|
11,797,025
|
|
|
|
10,841,262
|
|
|
Shares available for future grants under the 2024 Foundation plan
|
|
|
12,923
|
|
|
|
14,498
|
|
|
Shares subject to the employee share purchase plan
|
|
|
835,694
|
|
|
|
1,048,635
|
|
|
Total
|
|
|
58,674,928
|
|
|
|
65,719,181
|
|
|
| Schedule of share option activity |
| |
|
Number of Options
|
|
|
Weighted-Average Exercise Price
|
|
|
Weighted Average Remaining Contractual life
|
|
|
Aggregate Intrinsic Value
|
|
| |
|
(Unaudited)
|
|
|
Outstanding — January 1, 2026 (*)
|
|
|
1,257,067
|
|
|
$
|
70.64
|
|
|
|
5.17
|
|
|
$
|
111,600
|
|
|
Granted (*)
|
|
|
95,135
|
|
|
$
|
0.01
|
|
|
|
|
|
|
|
|
|
|
Exercised
|
|
|
(140,338
|
)
|
|
$
|
12.23
|
|
|
|
|
|
|
|
|
|
|
Expired and forfeited
|
|
|
(61,544
|
)
|
|
$
|
141.80
|
|
|
|
|
|
|
|
|
|
|
Outstanding — June 30, 2026
|
|
|
1,150,320
|
|
|
$
|
68.12
|
|
|
|
5.21
|
|
|
$
|
43,467
|
|
|
Exercisable — June 30, 2026 (*)
|
|
|
979,853
|
|
|
$
|
76.06
|
|
|
|
4.63
|
|
|
$
|
33,462
|
|
(*) Includes 73,074 performance options granted to the Company’s Co-CEOs in 2022, 74,108 in 2023, 22,481 in 2024, 20,217 in 2025, and 66,595 in 2026, as applicable.
|
| Schedule of unvested restricted stock units |
| |
|
Number of Units
|
|
|
Weighted-Average Fair Value
|
|
| |
|
(Unaudited)
|
|
|
Balance at January 1, 2026 (*)
|
|
|
1,396,897
|
|
|
$
|
221.68
|
|
|
Granted (*)
|
|
|
1,783,617
|
|
|
$
|
75.47
|
|
|
Vested
|
|
|
(362,312
|
)
|
|
$
|
178.92
|
|
|
Canceled
|
|
|
(213,355
|
)
|
|
$
|
199.23
|
|
|
Balance at June 30, 2026 (*)
|
|
|
2,604,847
|
|
|
$
|
129.35
|
|
(*) Includes 22,928 performance shares granted to the Company’s Co-CEOs in 2023, 48,129, 62,211 and 258,656 performance shares granted to the Company’s Co-CEOs and several executives in 2024, 2025 and 2026, respectively.
|
| Schedule of share-based compensation expense |
| |
|
Six months ended June 30,
|
|
| |
|
2026
|
|
|
2025
|
|
| |
|
(Unaudited)
|
|
|
Cost of revenue
|
|
$
|
3,311
|
|
|
$
|
3,406
|
|
|
Research and development
|
|
|
29,911
|
|
|
|
43,347
|
|
|
Sales and marketing
|
|
|
20,172
|
|
|
|
19,205
|
|
|
General and administrative
|
|
|
17,107
|
|
|
|
21,645
|
|
|
Share-based compensation, net of amounts capitalized
|
|
$
|
70,501
|
|
|
$
|
87,603
|
|
|
Capitalized share-based compensation expense
|
|
|
432
|
|
|
|
1,055
|
|
|
Total share-based compensation
|
|
$
|
70,933
|
|
|
$
|
88,658
|
|
|
| Schedule of black-scholes stock option assumptions used at the grant dates |
| |
|
Six months ended June 30,
|
|
| |
|
2026
|
|
|
2025
|
|
| |
|
(Unaudited)
|
|
|
Risk-free interest rate
|
|
|
3.89%-4.02%
|
|
|
|
3.74%-4.10%
|
|
|
Expected dividend yield
|
|
|
0%
|
|
|
|
0%
|
|
|
Expected term (in years)
|
|
|
5.5-7
|
|
|
|
2-7
|
|
|
Expected volatility
|
|
|
62.83%
|
|
|
|
57.02%-59.32%
|
|
|